PT1811036E - Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes - Google Patents

Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes Download PDF

Info

Publication number
PT1811036E
PT1811036E PT06027072T PT06027072T PT1811036E PT 1811036 E PT1811036 E PT 1811036E PT 06027072 T PT06027072 T PT 06027072T PT 06027072 T PT06027072 T PT 06027072T PT 1811036 E PT1811036 E PT 1811036E
Authority
PT
Portugal
Prior art keywords
cancer
antibody fragment
compositions
gene delivery
nucleic acid
Prior art date
Application number
PT06027072T
Other languages
English (en)
Inventor
Liang Xu
Esther H Chang
William Alexander
Cheng-Cheng Huang
Wenhua Tang
Original Assignee
Univ Georgetown
Synergene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Synergene Therapeutics Inc filed Critical Univ Georgetown
Publication of PT1811036E publication Critical patent/PT1811036E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
PT06027072T 1999-02-22 2000-02-22 Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes PT1811036E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12113399P 1999-02-22 1999-02-22

Publications (1)

Publication Number Publication Date
PT1811036E true PT1811036E (pt) 2011-07-11

Family

ID=22394769

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06027072T PT1811036E (pt) 1999-02-22 2000-02-22 Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes

Country Status (11)

Country Link
US (3) US7479276B1 (pt)
EP (3) EP1154756B1 (pt)
JP (2) JP4799736B2 (pt)
AT (2) ATE511543T1 (pt)
AU (1) AU3703100A (pt)
CA (1) CA2362550C (pt)
DE (1) DE60032739T2 (pt)
ES (2) ES2366100T3 (pt)
HK (1) HK1106952A1 (pt)
PT (1) PT1811036E (pt)
WO (1) WO2000050008A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
DE10061110B4 (de) * 2000-12-07 2006-12-21 Schaller, Gerhard, Prof. Dr. med. Expression der Keratingene 8 und 18 zur Therapie von Tumoren, insbesondere des Mammakarzinoms
AU2002307035A1 (en) * 2001-04-02 2002-10-15 Georgetown University A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
JP2006517032A (ja) * 2003-01-28 2006-07-13 ジョージタウン・ユニバーシティ ある種の癌治療の有効性を評価するための方法
PL1633327T3 (pl) * 2003-06-04 2011-02-28 Univ Georgetown Sposób poprawienia stabilności i okresu trwałości kompleksów liposomowych
CA2638899C (en) * 2005-10-20 2016-01-05 Georgetown University Tumor-targeted nanodelivery systems to improve early mri detection of cancer
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CA2652222A1 (en) * 2006-05-15 2007-12-13 Georgetown University Preparation of antibody- or antibody-fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
WO2009009054A1 (en) 2007-07-09 2009-01-15 Georgetown University Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
JP4934531B2 (ja) * 2007-07-11 2012-05-16 株式会社日立製作所 アナログデジタル変換器及びその制御方法並びに無線トランシーバ回路
US20110269942A1 (en) * 2007-08-09 2011-11-03 Daiichi Sankyo Company, Limited Antibodies modified with hydrophobic molecule
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
JP2011516094A (ja) 2008-04-15 2011-05-26 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
KR102099462B1 (ko) 2010-11-30 2020-04-10 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
CA2826594C (en) 2011-02-03 2019-09-17 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2014046630A1 (en) 2012-09-19 2014-03-27 Keskin, Dilek Tumor targeted liposomal drug delivery system
BR102013004109A2 (pt) * 2012-09-19 2015-06-23 Univ Georgetown Lipossomas direcionados
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
AU2013318338B2 (en) 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
US9878055B2 (en) 2013-03-14 2018-01-30 Georgetown University Treatment for exposure to nerve agent
KR20170075742A (ko) 2014-10-02 2017-07-03 프로티바 바이오쎄라퓨틱스, 인코포레이티드 B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법
WO2016164827A1 (en) 2015-04-09 2016-10-13 Bikanta Corporation Imaging systems and methods using fluorescent nanodiamonds
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
SG11201806868TA (en) 2016-02-25 2018-09-27 Applied Biological Laboratories Inc Compositions and methods for protecting against airborne pathogens and irritants
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3439695B1 (en) 2016-04-04 2022-05-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
CA3060442A1 (en) * 2017-04-19 2018-10-25 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer
US20200239597A1 (en) * 2017-08-09 2020-07-30 Donald Newmeyer An anti-apoptotic function of pkm2 and intracellularly expressed scfv antibodies
WO2019113393A1 (en) 2017-12-06 2019-06-13 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
US20200113829A1 (en) * 2018-10-12 2020-04-16 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy
JP2023527638A (ja) 2020-03-27 2023-06-30 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
CN116509818A (zh) * 2023-04-18 2023-08-01 中国人民解放军军事科学院军事医学研究院 一种低毒性的脂溶性纳米粒组合物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
AU642980B2 (en) 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
US5705655A (en) 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5635380A (en) 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
AU704218B2 (en) 1994-05-20 1999-04-15 Board Of Trustees Of The Leland Stanford Junior University An autonomous replication system for mammalian cells
AU696881B2 (en) 1994-06-22 1998-09-24 Megabios Corporation Cationic amphiphiles
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
US20020051767A1 (en) 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6077834A (en) 1996-02-09 2000-06-20 Cheng; Pi-Wan Receptor ligand-facilitated delivery of biologically active molecules
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US6030956A (en) 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6071533A (en) 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
WO1999002647A2 (de) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Klonierungsvektoren für die herstellung von adenoviralen minimalviren
CA2348675A1 (en) 1997-10-24 1999-05-06 Warren Dang Methods for preparing polynucleotide transfection complexes
CN1191094C (zh) * 1997-11-19 2005-03-02 乔治敦大学 定向脂质体基因送递
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
AU4090299A (en) 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
WO1999060110A2 (en) * 1998-05-20 1999-11-25 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
DE69929074T2 (de) 1998-09-11 2006-08-10 Thomas Jefferson University Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen

Also Published As

Publication number Publication date
US20070065432A1 (en) 2007-03-22
CA2362550C (en) 2010-05-11
DE60032739T2 (de) 2007-05-24
EP1811036A2 (en) 2007-07-25
HK1106952A1 (en) 2008-03-20
US20090191261A1 (en) 2009-07-30
EP1154756A2 (en) 2001-11-21
ATE350012T1 (de) 2007-01-15
WO2000050008A2 (en) 2000-08-31
DE60032739D1 (de) 2007-02-15
EP1811036B8 (en) 2011-09-21
US7479276B1 (en) 2009-01-20
EP1811036A3 (en) 2007-08-01
EP1815848A1 (en) 2007-08-08
ES2278597T3 (es) 2007-08-16
JP5567466B2 (ja) 2014-08-06
ATE511543T1 (de) 2011-06-15
AU3703100A (en) 2000-09-14
ES2366100T3 (es) 2011-10-17
JP2011115167A (ja) 2011-06-16
CA2362550A1 (en) 2000-08-31
WO2000050008A3 (en) 2000-12-21
EP1154756B1 (en) 2007-01-03
JP2002537318A (ja) 2002-11-05
EP1811036B1 (en) 2011-06-01
JP4799736B2 (ja) 2011-10-26
WO2000050008A9 (en) 2002-06-27
US8859274B2 (en) 2014-10-14

Similar Documents

Publication Publication Date Title
HK1106952A1 (en) Antibody fragment-targeted immunoliposomes for systemic gene delivery
Azemar et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
Lammering et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance
EP0796277A4 (en) REAGENTS AND METHOD FOR OVEREXPRESSING MUTTED EPIDERMAL GROWTH FACTOR RECEPTORS
DK0970207T3 (da) Heregulin-varianter
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
EP2015758A4 (en) COMPOUNDS AND METHOD FOR MODULATING THE EXPRESSION OF APO-B
WO2001091805A3 (en) Compounds for targeting endothelial cells
UA102988C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
BR0314121A (pt) Composições nutricionais
NO20055209D0 (no) Peptabody for cancerbehandling
WO2006083797A3 (en) Improving and protecting cell therapy for neurological disorders including parkinson's disease
WO1999064594A8 (en) Genes and gene expression products that are differentially regulated in prostate cancer
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
WO1996008274A3 (en) Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
Jin et al. The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system
IL158184A0 (en) Anti-muc-1 single chain antibodies for tumor targeting
Gaidamakova et al. Molecular vehicle for target-mediated delivery of therapeutics and diagnostics
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
WO2006029406A3 (en) Methods for treating bone tumors using bone morphogenic proteins
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid